Merck: There’s more to us than Keytruda. Really

Put this in the category of good problems to have: In its first four years on the market, Keytruda, made by Merck, has had the best sales launch in the history of cancer drugs.

In the third quarter of 2018, Merck reported sales of $1.9 billion of the checkpoint inhibitor, 18 percent of the company’s total revenue. Keytruda sales have now surpassed those of Opdivo, a similar medicine from Bristol-Myers Squibb. According to projections collected by Evaluate Pharma and touted by Merck, full-year sales of Keytruda will approach $7 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

I am not impressed with the knowledge that your company made so much money for a drug that is supposed to help people with a serious disease as Cancer is. This drug did NOT do my son any good after 11 months but cause him alot of side effects . It’s a shame that you are able to brag about the money made from this. Unbelievable!!!